Analysts think CLDX stock price could increase by 237%
Mar 03, 2025, 12:26 PM
-18.08%
What does CLDX do
Celldex Therapeutics, based in Hampton, New Jersey, develops novel therapeutics targeting mast cell-mediated diseases and employs 160 staff. Their pipeline includes Barzolvolimab and the bispecific antibody CDX-585 for inflammatory diseases and oncology.
13 analysts think CLDX stock price will increase by 237.19%. The current median analyst target is $69.36 compared to a current stock price of $20.57. The lowest analysts target is $36.36 and the highest analyst target is $94.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.